Status:
TERMINATED
Side Effects of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) Directed Therapy
Lead Sponsor:
University Medical Center Groningen
Conditions:
Metastatic Malignancies
Eligibility:
All Genders
18+ years
Brief Summary
Angiogenesis inhibitors and EGFR inhibitors not only have anti tumor activity but also modify physiological processes. This study evaluates effects on vascular function, endocrine function and metabol...
Detailed Description
Background In recent years, multiple new agents have been developed that inhibit angiogenesis and the epidermal growth factor receptor (EGFR) signalling pathway. The cell signalling routes that are ...
Eligibility Criteria
Inclusion
- Patients who will start with an angiogenesis inhibitor or EGFR inhibitor
- Concomittant chemotherapy, immunotherapy or radiotherapy is allowed
- Age above 18 years at start of treatment
- Willingness to give written informed consent
Exclusion
- Unable to give written informed consent
- Age under 18 years
Key Trial Info
Start Date :
March 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT00657098
Start Date
March 1 2008
End Date
October 1 2015
Last Update
May 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Groningen
Groningen, Netherlands, 9700 RB